Global Androgens and Anabolic Steroids Market – Industry Trends and Forecast to 2030

Global Androgens and Anabolic Steroids Market, By Indication (Anaemia, Breast Cancer, Hypogonadism, Others), Drugs (Oxymetholone, Methyltestosterone, Testosterone, Others), Type (Prescription drugs, Over-the-counter (OTC) drugs), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Androgens and Anabolic Steroids Market Analysis and Size

According to the recent data, one-fourth of the global population is estimated to be anemic, with cases increasing rapidly for women, expectant mothers, young girls, and children younger than age 5. In 2021, 1.92 billion people globally had anemia. This is an increase of 420 million cases over three decades.

Data Bridge Market Research analyses that the androgens and anabolic steroids market which was USD 62.77 billion in 2022, is likely to reach USD 146.76 billion by 2030, and is expected to undergo a CAGR of 11.2% during the forecast period. “Anaemia” dominates the indication segment of the androgens and anabolic steroids market owing to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

The male sex hormones testosterone and dihydrotestosterone, as well as other agents that act like these sex hormones, are forms of androgens and anabolic steroids. They promote the growth of male sexual features (such as a deeper voice and a longer beard) as well as male sex organs. Replacement therapy with androgens and anabolic steroids is used to treat delayed puberty in teenage males, breast cancer in women and hypogonadism as well as impotence in men. They're also used to treat anemia, osteoporosis, weight loss, and other hormonally imbalanced disorders.

Global  Androgens and Anabolic Steroids Market Dynamics

Drivers

• Increasing prevalence of hypogonadism in males

The increasing prevalence of hypogonadism in males will fuel industry growth. In men, hypogonadism is caused by a lack of testosterone, which has a negative impact on their quality of life and different organ functioning. When men are unable to erect, they are said to be impotent. Tiredness, lack of sleep, anxiety, and excessive alcohol use are the leading causes of impotence in men. Breast cancer is the uncontrolled development of cells in the breast in women. These cells grow into a tumor, which can be felt as a lump or seen on an X-ray. Malignant cancer occurs when these cells infect neighboring tissues.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of androgens and anabolic steroids market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Opportunities

• Expanding Indications

There is potential for the expansion of indications for androgens and anabolic steroids. Research is ongoing to explore their use in treating various medical conditions, such as muscle wasting disorders, osteoporosis, and certain hormonal imbalances.

• Innovations in Delivery Systems

Developing novel and convenient delivery systems for androgens and anabolic steroids, such as transdermal patches or long-acting injectable, can improve patient compliance and the overall therapeutic experience.

Restraints/Challenges

• Misuse and Abuse

One of the primary challenges in this market is the misuse and abuse of androgens and anabolic steroids, especially in the context of sports and bodybuilding. This can lead to serious health risks, including cardiovascular problems, liver damage, and psychological issues.

• Health Risks

The use of anabolic steroids, particularly when taken in excessive doses or for extended periods, can lead to a range of adverse health effects, such as cardiovascular disease, liver damage, kidney problems, and psychiatric disorders.

This androgens and anabolic steroids market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the androgens and anabolic steroids market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In April, 2019, Teva Pharmaceuticals launched a generic version of testosterone gel, Testosterone Gel 1.62% CIII which has been indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone

Global Androgens and Anabolic Steroids Market Scope

The androgens and anabolic steroids market is segmented on the basis of indication, drugs, type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Anaemia
• Breast Cancer
• Hypogonadism
• Others

Drugs

• Oxymetholone
• Methyltestosterone
• Testosterone
• Others

Type

• Prescription drugs
• Over-the-counter (OTC) drugs

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Androgens and Anabolic Steroids Market Regional Analysis/Insights

The global androgens and anabolic steroids market is analysed and market size insights and trends are provided by country, indication, drugs, type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the androgens and anabolic steroids market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East & Africa.

North America is expected to dominate the androgens and anabolic steroids market because of the growing prevalence of breast cancer population and rising healthcare expenditure will further propel the market’s growth rate in this region. In addition, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the surging level of disposable income in this region. Also, development of healthcare infrastructure and rising number of generic drug manufacturer will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The androgens and anabolic steroids market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the androgens and anabolic steroids market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the androgens and anabolic steroids market.

Competitive Landscape and Androgens and Anabolic Steroids Market Share Analysis

The androgens and anabolic steroids market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the androgens and anabolic steroids market.

Some of the major players operating in the androgens and anabolic steroids market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Dr. Reddy’s Laboratories Ltd. (India)
• Aurobindo Pharma (India)
• Endo International plc (Ireland)
• AbbVie Inc. (U.S.)
• Allergan (Ireland)
• Eli Lilly and Company (U.S.)
• Cipla Inc. (U.S.)
• Lupin (India)